Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nkarta, Inc.NKTX · Entity 6346 | Director · Chief Executive Officer | June 18, 2026 | June 22, 2026 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Chairman & CEO | October 10, 2017 | October 12, 2017 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | June 12, 2024 | June 13, 2024 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director | June 08, 2018 | June 11, 2018 |
| enGene Therapeutics Inc.ENGN · Entity 6638 | Director | June 16, 2026 | June 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nkarta, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 390,247 |
Reported balance
After 2026-06-18 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-18 · Sale · Disposed 1,776 · Balance 390,247 F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person.
F2: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2026.
OncoMed Pharmaceuticals Inc
Report date October 10, 2017 · Filed October 12, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 76,188 |
Last balance in matching sequence
After 2017-10-10 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-10-10 · Sale · Disposed 52 · Balance 77,534 F1: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2: Includes 55,500 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. Row 2 · 2017-10-10 · Sale · Disposed 1,346 · Balance 76,188 F1: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes. F2: Includes 55,500 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 324,840 |
Reported balance
Holding disclosure · report date 2017-10-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 324,840 F3: The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a sell-to-cover election made by the Reporting Person at the time of the initial grant of the restricted stock unit ("RSU") award, the shares were sold upon the vesting of restricted stock units solely to cover applicable withholding taxes.
F2: Includes 55,500 RSUs. The Reporting Person is entitled to receive one (1) share of common stock of the issuer for each one (1) RSU upon the vesting thereof.
F3: The shares are held by Paul J. Hastings & Steve N. De Jong, Trustors and/or TTEES, The Hastings-De Jong Lv Tr DTD May 1, 2012.
Pacira BioSciences, Inc.
Report date June 12, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,724 |
Ending reported balance
After 2024-06-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-12 · Grant · Acquired 5,230 · Balance 13,604 F1: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Row 2 · 2024-06-13 · Sale · Disposed 880 · Balance 12,724 F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.68 · Expires 2034-06-12 | Direct | 12,179 |
Reported balance
After 2024-06-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-12 · Grant · Acquired 12,179 · Balance 12,179 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Protara Therapeutics, Inc.
Report date June 08, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-07 | Direct | 12,700 |
Reported balance
After 2018-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-08 · Grant · Acquired 12,700 · Balance 12,700 F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.
enGene Therapeutics Inc.
Report date June 16, 2026 · Filed June 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.75 · Expires 2036-06-16 | Direct | 31,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 31,000 · Balance 31,000 F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 22, 2026 20:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,776 | $2.71 | $4,812.96 |
DisclosureSEC source: 0001193125-26-277507 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,247 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2026. Read SEC document |
| June 16, 2026 Filed Jun 17, 2026 21:39 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0000929638-26-002259 · form4.xml · derivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Shares · 31,000 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option vests fully on the earlier of (i) the first anniversary of the vesting commencement date, which was June 9, 2026 or (ii) the registrant's 2027 annual meeting of shareholders. Read SEC document |
| January 15, 2026 Filed Jan 20, 2026 22:39 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 26,046 | $2.07 | $53,915.22 |
DisclosureSEC source: 0001193125-26-016865 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,023 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:48 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 562,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001193125-26-007896 · ownership.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,000 Underlying: Common Stock · 562,000 shares Expires 2036-01-05 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2026. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 22:48 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 94,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-007896 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,069 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2027. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2025. Read SEC document |
| June 18, 2025 Filed Jun 20, 2025 20:08 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,790 | $1.79 | $3,204.10 |
DisclosureSEC source: 0000950170-25-088501 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 320,069 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.76 to $1.79. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2025. Read SEC document |
| June 16, 2025 Filed Jun 16, 2025 22:38 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000929638-25-002250 · form4.xml · derivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Shares · 22,500 shares Expires 2035-06-16 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) the first anniversary of the date vesting commenced, which was June 10, 2025; or (ii) the 2026 Annual Meeting of Shareholders.. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 377,000 | $0.00 Strike: $1.83 | $0.00 |
DisclosureSEC source: 0000950170-25-083708 · ownership.xml · derivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 377,000 Underlying: Common Stock · 377,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: The option is scheduled to vest and become exercisable as to 40% of the shares subject to the grant on June 5, 2026. The remaining 60% of the shares subject to the grant is scheduled to vest and become exercisable on June 5, 2027. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 22:35 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 17,378 | $2.20 | $38,231.60 |
DisclosureSEC source: 0000950170-25-006824 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,859 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 565,500 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0000950170-25-002827 · ownership.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 565,500 Underlying: Common Stock · 565,500 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2025. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 94,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002827 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 337,237 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2026. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 2,000 shares acquired on May 31, 2024 and 2,000 shares acquired on November 30, 2024, in each case under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| June 18, 2024 Filed Jun 20, 2024 21:03 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,770 | $5.60 | $9,912.00 |
DisclosureSEC source: 0000950170-24-075732 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,737 F1 · shares: Represents shares sold as required by the applicable award terms to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.58 to $5.60. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 15, 2024 Filed Jun 18, 2024 20:08 UTC | enGene Therapeutics Inc. ENGN · Entity 6638 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $9.00 | $0.00 |
DisclosureSEC source: 0000929638-24-002216 · form4.xml · derivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-06-15 F1 · derivative.exercise_date: This option vests at 1/3 on each of the first, second and third anniversaries of the date vesting commenced, which was May 15, 2024. Read SEC document |
| June 13, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 880 | $28.38 | $24,974.40 |
DisclosureSEC source: 0001396814-24-000075 · wk-form4_1718316771.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,724 F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,179 | $0.00 Strike: $28.68 | $0.00 |
DisclosureSEC source: 0001396814-24-000075 · wk-form4_1718316771.xml · derivative · entry 3 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,179 Underlying: Common Stock · 12,179 shares Expires 2034-06-12 Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 22:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001396814-24-000075 · wk-form4_1718316771.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,604 F1 · shares: Represents restricted stock units that vest on June 12, 2025, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 21:33 UTC | Nkarta, Inc. NKTX · Entity 6346 | Disposition to issuerCommon Stock | 137,642 | $13.33 | $1,834,767.86 |
DisclosureSEC source: 0000950170-24-026055 · ownership.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,507 F1 · kind: The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and most recently amended on June 27, 2022. F3 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.85. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:33 UTC | Nkarta, Inc. NKTX · Entity 6346 | Disposition to issuerCommon Stock | 12,358 | $13.00 | $160,654.00 |
DisclosureSEC source: 0000950170-24-026055 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 378,149 F1 · kind: The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and most recently amended on June 27, 2022. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.01. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 21:40 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 9,697 | $8.74 | $84,751.78 |
DisclosureSEC source: 0000950170-24-005426 · ownership.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 390,507 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $8.74 to $8.96. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:47 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 509,500 | $0.00 Strike: $6.01 | $0.00 |
DisclosureSEC source: 0001209191-24-001160 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 509,500 Underlying: Common Stock · 509,500 shares Expires 2034-01-03 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2024. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 21:47 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001160 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,204 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2025. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 1,802 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2023. Read SEC document |
| June 20, 2023 Filed Jun 22, 2023 20:20 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 1,704 | $4.85 | $8,264.40 |
DisclosureSEC source: 0001209191-23-039051 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 313,402 F1 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units and does not represent a discretionary transaction by the Reporting Person. F2 · balance_after: Includes 2,000 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on May 31, 2023. Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,925 | $0.00 Strike: $38.74 | $0.00 |
DisclosureSEC source: 0001209191-23-038023 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,925 Underlying: Common Stock · 12,925 shares Expires 2033-06-14 Read SEC document |
| June 14, 2023 Filed Jun 16, 2023 21:32 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038023 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,374 F1 · shares: Represents restricted stock units that vest on June 3, 2024, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2023 Filed Jun 8, 2023 01:23 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 580 | $38.34 | $22,236.62 |
DisclosureSEC source: 0001209191-23-035257 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,599 Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,000 | $0.00 Strike: $29.90 | $0.00 |
DisclosureSEC source: 0001209191-23-030141 · doc4.xml · derivative · entry 3 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,000 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · derivative.exercise_date: The stock option vested and became exercisable in twelve equal monthly installments, with the first installment being on July 12, 2013. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,000 | $41.85 | $292,950.00 |
DisclosureSEC source: 0001209191-23-030141 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,179 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| May 15, 2023 Filed May 17, 2023 20:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,000 | $29.90 | $209,300.00 |
DisclosureSEC source: 0001209191-23-030141 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,179 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 17, 2023 Filed Jan 19, 2023 00:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 3,691 | $5.49 | $20,263.59 |
DisclosureSEC source: 0001209191-23-003853 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,106 F3 · shares: Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction by the Reporting Person. F4 · price: This transaction was executed in multiple trades at prices ranging from $5.49 to $5.56. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. F2 · balance_after: Includes 1,836 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 00:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 386,500 | $0.00 Strike: $5.57 | $0.00 |
DisclosureSEC source: 0001209191-23-003853 · doc4.xml · derivative · entry 3 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 386,500 Underlying: Common Stock · 386,500 shares Expires 2033-01-12 F5 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2023. Read SEC document |
| January 13, 2023 Filed Jan 19, 2023 00:04 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 64,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003853 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 316,797 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2024. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 1,836 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on November 30, 2022. Read SEC document |
| September 29, 2022 Filed Sep 30, 2022 20:30 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 498 | $13.00 | $6,474.00 |
DisclosureSEC source: 0000899243-22-032306 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,461 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the trade date. Read SEC document |
| September 28, 2022 Filed Sep 30, 2022 20:30 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 23,376 | $13.03 | $304,614.99 |
DisclosureSEC source: 0000899243-22-032306 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,959 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the trade date. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.09. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 21, 2022 Filed Sep 22, 2022 21:32 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 6,126 | $13.01 | $79,717.03 |
DisclosureSEC source: 0000899243-22-031711 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,335 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the trade date. F2 · price: This transaction was executed in multiple trades at prices ranging from $13.00 to $13.07. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 20:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 533 | $56.95 | $30,354.35 |
DisclosureSEC source: 0001209191-22-042037 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,179 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 23:11 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $12.25 | $0.00 |
DisclosureSEC source: 0001209191-22-038532 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2032-06-16 F2 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 17, 2022. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 23:11 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038532 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,461 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,225 | $0.00 Strike: $59.39 | $0.00 |
DisclosureSEC source: 0001209191-22-035223 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,225 Underlying: Common Stock · 8,225 shares Expires 2032-06-08 Read SEC document |
| June 08, 2022 Filed Jun 8, 2022 23:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-035223 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,712 F1 · shares: Represents restricted stock units that vest on June 3, 2023, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 21:53 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantStock Option (right to buy) · Derivative | 251,100 | $0.00 Strike: $12.14 | $0.00 |
DisclosureSEC source: 0001209191-22-003759 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,100 Underlying: Common Stock · 251,100 shares Expires 2032-01-13 F3 · derivative.exercise_date: This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2022. Read SEC document |
| January 14, 2022 Filed Jan 19, 2022 21:53 UTC | Nkarta, Inc. NKTX · Entity 6346 | GrantCommon Stock | 41,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003759 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,961 F1 · shares: Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. F2 · balance_after: Includes 7,714 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:35 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 223 | $26.53 | $5,916.19 |
DisclosureSEC source: 0000899243-21-038637 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,061 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F3 · balance_after: Includes 19,285 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| September 29, 2021 Filed Oct 1, 2021 20:35 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 8,277 | $27.20 | $225,134.40 |
DisclosureSEC source: 0000899243-21-038637 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,284 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.65 to $27.58, inclusive. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F3 · balance_after: Includes 19,285 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 3,807 | $26.89 | $102,370.23 |
DisclosureSEC source: 0000899243-21-025505 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,561 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F3 · price: This transaction was executed in multiple trades at prices ranging from $26.74 to $27.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Includes 30,856 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| June 21, 2021 Filed Jun 23, 2021 20:05 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 4,693 | $26.39 | $123,848.27 |
DisclosureSEC source: 0000899243-21-025505 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,368 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F2 · price: This transaction was executed in multiple trades at prices ranging from $25.72 to $26.71. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F4 · balance_after: Includes 30,856 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 7,626 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040084 · doc4.xml · derivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,626 Underlying: Common Stock · 7,626 shares Expires 2031-06-09 Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040084 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,552 F1 · shares: Represents restricted stock units that vest on June 3, 2022, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 630 | $62.19 | $39,179.70 |
DisclosureSEC source: 0001209191-21-038878 · doc4.xml · nonDerivative · entry 1 HASTINGS PAUL J · CIK 0001309702 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,486 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 10:15 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 3,130 | $32.21 | $100,817.30 |
DisclosureSEC source: 0000899243-21-014312 · doc4.xml · nonDerivative · entry 3 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,061 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F4 · price: This transaction was executed in multiple trades at prices ranging from $32.00 to $32.83. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · balance_after: Includes 42,427 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 10:15 UTC | Nkarta, Inc. NKTX · Entity 6346 | SaleCommon Stock | 2,409 | $31.24 | $75,257.16 |
DisclosureSEC source: 0000899243-21-014312 · doc4.xml · nonDerivative · entry 2 HASTINGS PAUL J · CIK 0001309702 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,191 F1 · kind: The transactions reported in this Form 4 were effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person at least 90 days prior to the trading date. F3 · price: This transaction was executed in multiple trades at prices ranging from $31.05 to $31.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F5 · balance_after: Includes 42,427 shares acquired upon early exercise of an option, which are subject to forfeiture until they vest. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.